Policosanol

What it is

Policosanol is a mixture of long-chain primary aliphatic alcohols, mainly octacosanol together with hexacosanol and triacontanol, extracted from plant wax. The best-studied product is Cuban, purified from sugar cane wax; other preparations are made from other plant sources and are not chemically identical. Chain lengths in the Cuban material run from 24 to 34 carbon atoms.

What the research says

This is one of the sharpest disagreements in the supplement literature, and it splits by who ran the trial. Cuban trials since the 1990s reported LDL-cholesterol falls comparable to statins, and Cuban and Korean trials have reported blood-pressure reductions. Independent North American and European replications of the cholesterol effect have failed: a US randomised trial of 20 mg/day for 8 weeks found no change at all in LDL-cholesterol or any other lipid. A 2025 dose-response meta-analysis of 21 trials found no effect on serum creatinine. No trial has measured heart attacks or strokes.

Evidence grade: Disputed.

What goes wrong

Adverse events were reported by eight of the 200 patients randomised in the grade I hypertension stratum (100 per group) over 12 weeks, with headache reported only in the policosanol arm. (Source 1)

• Randomized trial, Low certainty.
• Size: 200 patients in the grade I hypertension stratum (100 policosanol, 100 placebo), from 400 randomised across both strata.
• Who: Cuban patients with grade I hypertension.
• How long: 12 weeks.
• Result: 8 patients reported an adverse event (5 policosanol, 3 placebo); by type, headache 4 policosanol vs 0 placebo, sciatic pain 1 vs 0; three events were moderate and required paracetamol; no patient discontinued because of an adverse event.
• Funding: supported by the National Centre for Scientific Research (Cuba)

Limit of this finding: Eight adverse events among 200 people over 12 weeks is a very low rate for any trial, including placebo groups, so this is weak evidence that policosanol is well tolerated rather than proof of it. The count covers 12 weeks only, in Cuban patients with grade I hypertension, in a trial run by the institution that developed the product; it says nothing about longer use, other populations, or use alongside other medicines.

Only eight patients reported some AE (5 from the policosanol group, 3 from the placebo group) (Table 6). Of these, three were classified as moderate because they required paracetamol for headache or sciatic pain.

What the evidence supports

In a Korean randomised, double-blind, placebo-controlled trial, 24 weeks of Cuban policosanol lowered systolic blood pressure and total cholesterol and raised HDL-cholesterol. (Source 2)

• Randomized trial, Low certainty.
• Size: 84 healthy participants randomised to 10 mg, 20 mg or placebo.
• Who: healthy Korean adults with pre-hypertension (systolic 120-139 mmHg, diastolic 85-89 mmHg)
• How long: 24 weeks.
• Result: 20 mg group systolic 138 +/- 12 to 126 +/- 13 mmHg (p < 0.0001); total cholesterol fell about 8% on 10 mg (p = 0.029) and 13% on 20 mg (p = 0.0004); HDL-C rose up to 16% (10 mg, p = 0.002) and 12% (20 mg, p = 0.035)
• Funding: Korean National Research Foundation Medical Research Center Program grant; authors declare no commercial or financial conflict.

the policosanol 20 mg group showed the most significant reduction in average systolic BP (SBP) from 138 ± 12 mmHg at week 0 to 126 ± 13 mmHg at week 24 (p < 0.0001)

In a 400-patient Cuban multicentre trial, policosanol 20 mg/day for 12 weeks lowered systolic and diastolic blood pressure in the grade I hypertension stratum. (Source 3)

• Randomized trial, Low certainty.
• Size: 400 randomised across two strata; this report covers the 200-patient grade I hypertension stratum.
• Who: Cuban patients with grade I hypertension (SBP 140-159 mmHg, DBP 90-99 mmHg)
• How long: 12 weeks.
• Result: SBP lowered by more than 10 mmHg versus baseline and placebo (p < 0.001); 74% of policosanol patients reached SBP reductions >=10 mmHg vs 12% on placebo, and 91% reached DBP reductions >=5 mmHg vs 15% on placebo.
• Funding: supported by the National Centre for Scientific Research (Cuba), the institution that developed the product; authors declare no conflicts of interest.

Also, more (p < 0.001) policosanol patients reached SBP reductions ≥10 mmHg and DBP reductions ≥5 mmHg versus baseline (74% and 91%, respectively) than placebo patients (12% and 15%, respectively).

In a laboratory sub-analysis of participants from an existing randomised Cuban policosanol trial, 12 weeks of policosanol increased HDL cholesterol efflux capacity, a laboratory measure of HDL function, in 32 healthy Japanese adults. (Source 4)

• Randomized trial, Very low certainty.
• Size: 32 participants (17 placebo, 15 policosanol)
• Who: healthy Japanese adults.
• How long: 12 weeks.
• Result: HDL cholesterol efflux capacity, HDL-C and apolipoprotein A-I all increased; effect on efflux capacity seen in participants with high baseline HDL-C.
• Funding: partly funded by Fukuoka University; authors declare no commercial or financial conflict of interest.

Limit of this finding: This is not an independent trial. It is a lipoprotein sub-analysis of blood samples from people already enrolled in a randomised Cuban policosanol trial, so it does not count as a separate replication of that trial. Its outcome is a laboratory measure of how well HDL particles accept cholesterol, not a clinical event: no heart attack, stroke or death was measured. The schema's list of study designs has no value for a secondary analysis of a trial, so it is recorded as rct because the underlying comparison was randomised and placebo-controlled.

Cuban policosanol considerably increased the HDL CEC and HDL-C and apolipoprotein A-I (ApoA-I) levels.

What the evidence does not support

In a US randomised controlled trial, 20 mg/day of sugar cane policosanol for 8 weeks produced no change in LDL-cholesterol or in any secondary lipid or inflammatory measure. (Source 5)

• Randomized trial, Moderate certainty.
• Size: 40 participants (20 policosanol, 20 placebo)
• Who: ambulatory, community-dwelling healthy US adults with mild hypercholesterolaemia.
• How long: 8 weeks.
• Result: No significant difference in LDL-cholesterol change; placebo 3.87 to 3.59 mmol/L (-7.2%) vs policosanol 4.02 to 3.73 mmol/L (-7.7%); no significant change in total cholesterol, HDL, triacylglycerol, C-reactive protein or NMR lipoprotein profile.
• Funding: independent of the manufacturer: grant from The Charlotte-Mecklenburg Health Services Foundation; medication and placebo provided by Garuda International.

No significant differences in the change in LDL cholesterol were observed between the placebo (n = 20) and policosanol (n = 20) groups.

The abstract of a dose-response meta-analysis reports that policosanol had no significant effect on serum creatinine across twenty-one randomised trials. (Source 6)

• Meta-analysis, High certainty.
• Size: 2,427 participants across twenty-one randomised controlled trials, as stated in the abstract.
• Who: adults in randomised trials of policosanol supplementation.
• How long: trials of varying length, with subgroups above and below 24 weeks.
• Result: WMD = 0.21 micromol/l (95% CI -0.85 to 1.26; P = 0.70); low heterogeneity (I-squared 18.1%, P = 0.21)
• Funding: not stated in the available text.

Limit of this finding: The paper does not agree with itself about how much evidence it pools. The abstract says 2427 participants in twenty-one RCTs, which is the figure quoted here; the full text's Study characteristics section says 22 included RCTs (one crossover and 21 parallel) and 2462 individuals. The discrepancy is in the published paper, not in the quotation. It does not change the direction of the pooled result, but it does mean the exact amount of evidence behind that result is uncertain.

A meta-analysis showed that policosanol had no significant change in creatinine levels in participants consuming policosanol compared to placebo consumers (WMD = 0.21 µmol/l; 95% CI = − 0.85 to 1.26; P = 0.70).

Where the research disagrees

Whether policosanol lowers LDL-cholesterol

• Dulin and colleagues, American Journal of Clinical Nutrition (2006), double-blind randomised controlled trial, 40 US adults, 8 weeks: Policosanol does not alter the serum lipid profile over an 8-wk period in adults with mild hypercholesterolemia. (Source 5)
• The Cuban trial programme, as summarised in the same paper, a series of trials conducted in Cuba by the group that developed the product: The use of policosanol to treat elevated cholesterol is based on clinical trials conducted in Cuba, which showed sugar cane–derived policosanol to be similar in efficacy to statins. (Source 5)

How much

• Reference intake: No body has set a reference intake for policosanol. It is not an essential nutrient; it is described in the literature simply as a compound generated from sugar cane consisting of long-chain alcohols. (Source 6)
• Upper limit: No tolerable upper intake level or acceptable daily intake has been set for policosanol by any body we could reach. The highest daily amount used in the randomised trials we read was 20 mg/day. (Source 2)
• Studied: 20 mg once daily for 8 weeks in US adults with mild hypercholesterolaemia (no lipid effect) (Source 5)
• Studied: 10 mg or 20 mg daily for 24 weeks in Korean adults with pre-hypertension (Source 2)
• Studied: 20 mg/day for 12 weeks in Cuban patients with grade I hypertension (Source 3)

A common belief, and what the research shows

The belief: Policosanol is a proven natural alternative to statins for lowering cholesterol.

What the research shows: That belief traces to one country's trial programme. As the US replication trial puts it: "The use of policosanol to treat elevated cholesterol is based on clinical trials conducted in Cuba, which showed sugar cane–derived policosanol to be similar in efficacy to statins. Recent studies have challenged these findings, but there have been no trials conducted in North America that have examined the ability of sugar cane–derived policosanol to lower cholesterol." When that North American trial was run, the result was flat: "No significant differences in the change in LDL cholesterol were observed between the placebo (n = 20) and policosanol (n = 20) groups." Trials outside Cuba have more often found blood-pressure effects than cholesterol effects, and no trial has measured heart attacks or strokes.

Questions and answers

What is it?

Policosanol is not a single chemical but a mixture of long-chain fatty alcohols extracted from plant wax. The main components are octacosanol, hexacosanol and triacontanol. The most-studied version is purified from Cuban sugar cane wax; products from other plant sources have different mixtures. (Source 6)

What does it do in the body?

What it reliably does in the body is unsettled. Trials in Cuba, Korea and Japan report falls in blood pressure and improvements in cholesterol and HDL function; a US trial of the same 20 mg dose found no lipid change at all. The most consistently replicated signal outside Cuba is on blood pressure rather than cholesterol. (Source 2)

Is it good or bad for you?

Neither clearly. It appears well tolerated at the doses studied, with adverse events uncommon and no discontinuations in a 400-patient Cuban trial, but the headline cholesterol benefit did not survive independent replication. For someone taking it expecting statin-like cholesterol lowering, the best independent trial says it does nothing. (Source 5)

How do you get more of it?

Policosanol is taken as a supplement extracted from plant wax rather than eaten as a food in meaningful amounts. Trials have used defined doses: the Korean trial randomised people to 10 mg or 20 mg daily for 24 weeks, and the US and Cuban trials used 20 mg daily. (Source 2)

If it is harmful, what reduces it?

There is no described procedure for clearing policosanol from the body, and none is described as needed. In the 12-week Cuban trial of 200 patients with grade I hypertension, eight people reported an adverse event across both arms, three of them moderate enough to need paracetamol, and no one stopped the study because of one. Stopping the supplement is the only intervention described. (Source 1)

Why might someone be low in it or missing it?

There is no deficiency state. Policosanol is not made by the body and is not an essential nutrient; it is a purified plant wax fraction, so a person has none of it unless they take a preparation containing it. Cuban policosanol specifically is defined by its carbon chain length range, and other plant sources yield different mixtures. (Source 7)

Which whole foods contain it or feed it?

The source material is plant wax, chiefly sugar cane wax in the Cuban product; the alcohols themselves also occur in other plant waxes. No ordinary food is described in these trials as a practical source of the amounts used, which came from purified extracts. (Source 6)

What happens if you do not have it?

Nothing is described as going wrong if you never take policosanol. No deficiency syndrome exists in the literature, and the best independent trial found that adding it changed nothing in the lipid profile, so its absence has no measured consequence. (Source 5)

We searched: Searched for policosanol deficiency, requirement and essentiality alongside the 2006 American Journal of Clinical Nutrition trial and the 2025 BMC Complementary Medicine and Therapies dose-response meta-analysis; neither describes a deficiency state or an essential role.

How can you test for it?

No validated test for policosanol status exists in the literature we searched. Trials monitor the outcomes it is supposed to change - blood pressure, the lipid panel, and safety chemistry such as serum creatinine - rather than measuring policosanol itself. (Source 6)

We searched: Searched for a policosanol blood level, biomarker or status assay across the 2025 dose-response meta-analysis of 21 trials, the 2006 US randomised trial, the 2018 Korean trial and the 2025 Cuban hypertension trial; all measure downstream outcomes only.

References

1. The Journal of Clinical Hypertension. Policosanol (sugarcane wax alcohols) 20 mg/day in Cuban Patients With Grade I Hypertension: A Randomized, Double-Blind, Multicenter Study (adverse events section). 2025. PMID 41032504, DOI 10.1111/jch.70126. Read the source
2. Frontiers in Physiology. Long-Term Consumption of Cuban Policosanol Lowers Central and Brachial Blood Pressure and Improves Lipid Profile With Enhancement of Lipoprotein Properties in Healthy Korean Participants. 2018. DOI 10.3389/fphys.2018.00412. Read the source
3. The Journal of Clinical Hypertension. Policosanol (sugarcane wax alcohols) 20 mg/day in Cuban Patients With Grade I Hypertension: A Randomized, Double-Blind, Multicenter Study. 2025. PMID 41032504, DOI 10.1111/jch.70126. Read the source
4. Frontiers in Nutrition. Cuban policosanol improves high-density lipoprotein cholesterol efflux capacity in healthy Japanese subjects. 2024. DOI 10.3389/fnut.2023.1297008. Read the source
5. The American Journal of Clinical Nutrition. Policosanol is ineffective in the treatment of hypercholesterolemia: a randomized controlled trial. 2006. PMID 17158441, DOI 10.1093/ajcn/84.6.1543. Read the source
6. BMC Complementary Medicine and Therapies. The effects of policosanol supplementation on creatinine: a systematic review and dose–response meta-analysis of randomized controlled trials. 2025. DOI 10.1186/s12906-025-04911-0. Read the source
7. Frontiers in Nutrition. Cuban policosanol improves high-density lipoprotein cholesterol efflux capacity in healthy Japanese subjects (introduction, definition of policosanol). 2024. DOI 10.3389/fnut.2023.1297008. Read the source